European Parliament vote could deter investors from medical device technology
This article was originally published in Clinica
Executive Summary
The regulatory costs for devices that would be hit by the European Parliament's vote to favour the primacy of pharmaceutical legislation over other legislation where there are cases of doubt could be "multiplied drastically". That is the fear of the European medical device industry association, Eucomed, which predicts a negative impact on the pace of development and the consequent downturn on investment in Europe in medical technology manufacturing. That is unless the European Parliament's vote is overturned by the European Council which is due to complete the final reading of the text early in 2004.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.